Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.
AML
Chemotherapy
Drug metabolism
Intrinsic/acquired chemoresistance
Precision medicine
Relapse
Resistance modalities
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
14 Jan 2021
14 Jan 2021
Historique:
received:
08
10
2020
accepted:
02
01
2021
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) remains a devastating disease with a 5-year survival rate of less than 30%. AML treatment has undergone significant changes in recent years, incorporating novel targeted therapies along with improvements in allogeneic bone marrow transplantation techniques. However, the standard of care remains cytarabine and anthracyclines, and the primary hindrance towards curative treatment is the frequent emergence of intrinsic and acquired anticancer drug resistance. In this respect, patients presenting with chemoresistant AML face dismal prognosis even with most advanced therapies. Herein, we aimed to explore the potential implementation of the characterization of chemoresistance mechanisms in individual AML patients towards efficacious personalized medicine. Towards the identification of tailored treatments for individual patients, we herein present the cases of relapsed AML patients, and compare them to patients displaying durable remissions following the same chemotherapeutic induction treatment. We quantified the expression levels of specific genes mediating drug transport and metabolism, nucleotide biosynthesis, and apoptosis, in order to decipher the molecular mechanisms underlying intrinsic and/or acquired chemoresistance modalities in relapsed patients. This was achieved by real-time PCR using patient cDNA, and could be readily implemented in the clinical setting. This analysis revealed pre-existing differences in gene expression levels between the relapsed patients and patients with lasting remissions, as well as drug-induced alterations at different relapse stages compared to diagnosis. Each of the relapsed patients displayed unique chemoresistance mechanisms following similar treatment protocols, which could have been missed in a large study aimed at identifying common drug resistance determinants. Our findings emphasize the need for standardized evaluation of key drug transport and metabolism genes as an integral component of routine AML management, thereby allowing for the selection of treatments of choice for individual patients. This approach could facilitate the design of efficacious personalized treatment regimens, thereby reducing relapse rates of therapy refractory disease.
Sections du résumé
BACKGROUND
BACKGROUND
Acute myeloid leukemia (AML) remains a devastating disease with a 5-year survival rate of less than 30%. AML treatment has undergone significant changes in recent years, incorporating novel targeted therapies along with improvements in allogeneic bone marrow transplantation techniques. However, the standard of care remains cytarabine and anthracyclines, and the primary hindrance towards curative treatment is the frequent emergence of intrinsic and acquired anticancer drug resistance. In this respect, patients presenting with chemoresistant AML face dismal prognosis even with most advanced therapies. Herein, we aimed to explore the potential implementation of the characterization of chemoresistance mechanisms in individual AML patients towards efficacious personalized medicine.
METHODS
METHODS
Towards the identification of tailored treatments for individual patients, we herein present the cases of relapsed AML patients, and compare them to patients displaying durable remissions following the same chemotherapeutic induction treatment. We quantified the expression levels of specific genes mediating drug transport and metabolism, nucleotide biosynthesis, and apoptosis, in order to decipher the molecular mechanisms underlying intrinsic and/or acquired chemoresistance modalities in relapsed patients. This was achieved by real-time PCR using patient cDNA, and could be readily implemented in the clinical setting.
RESULTS
RESULTS
This analysis revealed pre-existing differences in gene expression levels between the relapsed patients and patients with lasting remissions, as well as drug-induced alterations at different relapse stages compared to diagnosis. Each of the relapsed patients displayed unique chemoresistance mechanisms following similar treatment protocols, which could have been missed in a large study aimed at identifying common drug resistance determinants.
CONCLUSIONS
CONCLUSIONS
Our findings emphasize the need for standardized evaluation of key drug transport and metabolism genes as an integral component of routine AML management, thereby allowing for the selection of treatments of choice for individual patients. This approach could facilitate the design of efficacious personalized treatment regimens, thereby reducing relapse rates of therapy refractory disease.
Identifiants
pubmed: 33446189
doi: 10.1186/s12935-021-01746-w
pii: 10.1186/s12935-021-01746-w
pmc: PMC7809753
doi:
Types de publication
Journal Article
Langues
eng
Pagination
53Références
Phytother Res. 2010 Jan;24(1):146-9
pubmed: 19548284
Pharmacogenomics. 2015 Jul;16(8):877-90
pubmed: 26083014
Blood. 1997 May 15;89(10):3745-54
pubmed: 9160680
J Hum Genet. 2013 Jun;58(6):353-61
pubmed: 23677058
Exp Hematol. 2015 Jan;43(1):32-43.e1-35
pubmed: 25450514
Mol Pharmacol. 2003 Jan;63(1):65-72
pubmed: 12488537
Nat Med. 2010 Feb;16(2):214-8
pubmed: 20098429
Pharmaceutics. 2016 Feb 24;8(1):
pubmed: 26927160
Exp Hematol. 2009 Jun;37(6):649-58
pubmed: 19463767
J Hematol Oncol. 2019 Sep 18;12(1):100
pubmed: 31533852
Leukemia. 1993 Jul;7(7):1005-11
pubmed: 7686601
Cancer Res. 1999 Dec 1;59(23):5956-63
pubmed: 10606241
Cell Death Dis. 2018 Dec 13;9(12):1191
pubmed: 30546014
Blood. 2000 Aug 15;96(4):1517-24
pubmed: 10942400
Blood. 2007 May 15;109(10):4168-70
pubmed: 17227830
Blood Adv. 2018 Mar 13;2(5):462-469
pubmed: 29490977
Mol Cancer Ther. 2014 Jul;13(7):1690-703
pubmed: 24688051
Leuk Lymphoma. 2020 Apr;61(4):831-839
pubmed: 31809629
Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e871-e882
pubmed: 32792304
Pharmacogenomics. 2009 Oct;10(10):1657-74
pubmed: 19842938
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
Eur J Haematol. 1989 Nov;43(5):411-6
pubmed: 2612614
Clin Cancer Res. 2011 Oct 15;17(20):6417-27
pubmed: 22003069
Cancer Res. 2008 Sep 1;68(17):7050-8
pubmed: 18757419
Adv Cancer Res. 1998;72:197-233
pubmed: 9338077
Drug Resist Updat. 2020 Sep;52:100712
pubmed: 32599435
Mol Pharmacol. 2006 Apr;69(4):1499-505
pubmed: 16434618
Nat Med. 2018 Dec;24(12):1859-1866
pubmed: 30420752
Leuk Res Rep. 2018 Mar 27;9:42-44
pubmed: 29892548
Anticancer Res. 1999 Nov-Dec;19(6B):5111-5
pubmed: 10697518
FEBS Lett. 1997 Dec 15;419(2-3):263-7
pubmed: 9428647
Blood Adv. 2019 Dec 23;3(24):4326-4335
pubmed: 31869416
Cancer. 2020 Nov 1;126(21):4668-4677
pubmed: 32767757
Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7
pubmed: 2430286
Pharmacogenomics J. 2010 Oct;10(5):396-407
pubmed: 19997082
Med Res Rev. 2016 Mar;36(2):248-99
pubmed: 26286294
PLoS One. 2017 Sep 25;12(9):e0184922
pubmed: 28945807
Cancer Chemother Pharmacol. 1985;15(1):35-9
pubmed: 3891121
Cell Death Dis. 2012 Apr 05;3:e293
pubmed: 22476101
Xenobiotica. 2018 Sep;48(9):904-910
pubmed: 29027832
Leuk Lymphoma. 2003 Oct;44(10):1705-12
pubmed: 14692522
Clin Lymphoma Myeloma Leuk. 2020 May;20(5):277-288
pubmed: 32113891
Pharmacogenet Genomics. 2009 Jul;19(7):552-3
pubmed: 19512958
EXCLI J. 2015 Jan 19;14:95-108
pubmed: 26600742
Exp Cell Res. 2000 Apr 10;256(1):42-9
pubmed: 10739650
Gene. 2001 Jul 11;272(1-2):141-8
pubmed: 11470519
Leukemia. 2007 Jan;21(1):66-71
pubmed: 17051246
Cancer Res. 2007 Mar 1;67(5):2217-25
pubmed: 17332352
Front Oncol. 2020 Feb 28;10:262
pubmed: 32185132
Cancer Res. 2017 Apr 15;77(8):2102-2111
pubmed: 28209616
Clin Chim Acta. 2007 Feb;377(1-2):144-9
pubmed: 17097625
Arch Biochem Biophys. 2002 Jan 15;397(2):184-90
pubmed: 11795870
Oncol Rep. 2009 Dec;22(6):1527-31
pubmed: 19885609
Cell Death Dis. 2013 Aug 15;4:e767
pubmed: 23949216
Anticancer Drug Des. 1990 Nov;5(4):307-17
pubmed: 1963303
Cell Death Dis. 2014 Feb 20;5:e1067
pubmed: 24556682
Biochimie. 1984 May;66(5):333-52
pubmed: 6380596
J Biol Chem. 2010 Oct 29;285(44):33602-13
pubmed: 20724482
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Biochem Pharmacol. 2005 Jul 1;70(1):161-9
pubmed: 15919056
Hum Mol Genet. 2011 Oct 1;20(19):3852-66
pubmed: 21752829
Leukemia. 2010 Aug;24(8):1513-5
pubmed: 20508618
Med Res Rev. 2019 Jan;39(1):176-264
pubmed: 29809286
Drug Resist Updat. 2016 Jul;27:14-29
pubmed: 27449595
Blood. 1997 Jul 1;90(1):270-8
pubmed: 9207462
Drug Resist Updat. 2006 Aug-Oct;9(4-5):227-46
pubmed: 17092765
Oncotarget. 2015 Jan 20;6(2):1143-56
pubmed: 25544758
Leukemia. 2005 Feb;19(2):176-82
pubmed: 15592433
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Am J Hematol. 2018 Oct;93(10):1267-1291
pubmed: 30328165
Cancer Metastasis Rev. 2007 Mar;26(1):85-110
pubmed: 17345146
Oncotarget. 2017 Jul 11;8(28):45117-45132
pubmed: 28187461
Cancer. 2013 Aug 15;119(16):3076-83
pubmed: 23674237
Breast Cancer Res Treat. 2002 May;73(2):113-25
pubmed: 12088114
Drug Metab Lett. 2010 Dec;4(4):228-32
pubmed: 20670211
Oncotarget. 2017 Jun 13;8(24):38099-38112
pubmed: 28498820
Biochemistry. 1999 Aug 17;38(33):10793-800
pubmed: 10451375
Br J Haematol. 2005 Apr;129(2):210-20
pubmed: 15813849
Front Oncol. 2020 May 06;10:697
pubmed: 32435621
Leuk Res. 2019 Jan;76:15-23
pubmed: 30476680
Gen Pharmacol. 1996 Mar;27(2):251-5
pubmed: 8919638
Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1214-22
pubmed: 22132977
Blood. 1993 Jan 1;81(1):151-7
pubmed: 8417786
FASEB J. 2007 Nov;21(13):3592-605
pubmed: 17595345
J Natl Cancer Inst. 1994 Aug 3;86(15):1152-8
pubmed: 8028036
Oncogene. 2003 Oct 20;22(47):7524-36
pubmed: 14576856
Leukemia. 1997 Sep;11(9):1523-32
pubmed: 9305608
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385
pubmed: 30837712
Cells. 2020 Apr 27;9(5):
pubmed: 32349204
Cancer Res. 1991 Aug 15;51(16):4213-8
pubmed: 1678312
Int J Mol Sci. 2020 Jun 20;21(12):
pubmed: 32575682
Am J Pathol. 1999 Dec;155(6):1861-7
pubmed: 10595916
Oncogene. 2004 Nov 25;23(55):8941-9
pubmed: 15480431
Cancer Res. 2001 Oct 1;61(19):7225-32
pubmed: 11585759
Cell Tissue Res. 2000 Jul;301(1):143-52
pubmed: 10928287
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Drug Resist Updat. 2012 Aug;15(4):183-210
pubmed: 22921318
Cancer Res. 2009 Jan 1;69(1):178-84
pubmed: 19118001
Cancer Res. 2008 Apr 1;68(7):2349-57
pubmed: 18381442
Eur J Haematol. 2002 Sep;69(3):171-8
pubmed: 12406011
Ann Oncol. 2020 Jun;31(6):697-712
pubmed: 32171751
Blood. 2003 Aug 15;102(4):1466-73
pubmed: 12689934
Br J Haematol. 2002 Jun;117(4):860-8
pubmed: 12060121
Clin Transl Sci. 2016 Feb;9(1):51-9
pubmed: 26842729
Pharmacol Ther. 2005 Jul;107(1):1-30
pubmed: 15963349
Ann Hematol. 2014 Aug;93(8):1391-400
pubmed: 24705888
Eur J Haematol. 2016 Sep;97(3):239-44
pubmed: 26613208
Cancer Metastasis Rev. 2007 Mar;26(1):153-81
pubmed: 17333344
Leukemia. 1997 Dec;11(12):2066-74
pubmed: 9447822
Blood. 1993 Aug 15;82(4):1288-99
pubmed: 8102561
Clin Cancer Res. 2009 Mar 1;15(5):1762-9
pubmed: 19240178
Nat Med. 1997 Aug;3(8):922-4
pubmed: 9256287
Mol Cells. 1997 Apr 30;7(2):170-7
pubmed: 9163728
Nat Rev Mol Cell Biol. 2013 May;14(5):283-96
pubmed: 23609508
Nucleosides Nucleotides Nucleic Acids. 2017 Jan 2;36(1):7-30
pubmed: 27759477
J Korean Med Sci. 2015 Oct;30(10):1416-22
pubmed: 26425037
Anticancer Res. 1996 Mar-Apr;16(2):709-14
pubmed: 8687117
Biochem Pharmacol. 2003 Jan 15;65(2):237-47
pubmed: 12504799
Biochem Pharmacol. 1995 Mar 15;49(6):829-37
pubmed: 7702641
Cell Death Dis. 2019 May 17;10(6):390
pubmed: 31101804
Pharmacol Res. 2017 Mar;117:177-184
pubmed: 28025106
Cancer Discov. 2020 Apr;10(4):536-551
pubmed: 31974170
Cancer Res. 1991 Oct 1;51(19):5275-83
pubmed: 1717144
Mol Pharmacol. 2003 Dec;64(6):1452-62
pubmed: 14645676
Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15
pubmed: 16530731
Drug Resist Updat. 2016 Jan;24:23-33
pubmed: 26830313
Drug Resist Updat. 2019 Sep;46:100645
pubmed: 31585396
Oncol Rep. 2015 Jul;34(1):488-94
pubmed: 25955569
Blood. 2002 Feb 15;99(4):1373-80
pubmed: 11830489
Eur J Haematol. 2020 Nov;105(5):588-596
pubmed: 32659848
Cancer Res. 2005 Dec 1;65(23):10952-8
pubmed: 16322243
Int J Oncol. 2009 Apr;34(4):1165-71
pubmed: 19287976
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4608-12
pubmed: 1584797
Mol Pharmacol. 2012 Dec;82(6):1008-21
pubmed: 22826468
Cell Death Discov. 2020 Mar 11;6:12
pubmed: 32194992